Quinquevalent vanadium complex with two mol of vanoxonin ligated by the two catechols was shown to be the active structure for inhibition of thymidylate synthetase. The catechol group of vanoxonin as the essential moiety for the inhibition of enzyme was further confirmed by studies of structure-activity relationships using the enzyme obtained from Ehrlich ascites carcinoma cells of mice. Vanoxonin-vanadium complex showed competitive inhibition with respect to deoxyuridylic acid but uncompetitive to 5,10-methylenetetrahydrofolate.
As reported in previous papers1,2), a vanoxonin-vanadium complex had inhibitory activity against thymidylate synthetase and the structure of vanoxonin was determined to be L-N-(2,3-dihydroxybenzoyl)-threonyl-L-(N~'-acetyl-N~-hydroxy)ornithine.
In this paper, we report the structure and properties of vanoxonin-vanadium complexes, the active species as the inhibitor of thymidylate synthetase, the structure-activity relationships of vanoxonin-related compounds, and kinetic studies of inhibition of thymidylate synthetase by a vanoxonin-vanadium complex.
Results and Discussion

Structure and Properties of Vanoxonin-vanadium Complexes and the Active Species for the Inhibition of Thymidylate Synthetase
Vanoxonin formed a green complex with absorption maxima at 437 and 660 nm with quadrivalent vanadium (VOSO4) under anaerobic condition. The spectrum was changed by exposure to air and a purple complex with absorption maxima at 534 and 845 nm was finally formed (Fig. 1) . Addition of cysteine in equimolar amount to the vanadium to a solution of the purple complex regenerated the original green complex. The purple complex was also prepared by reaction of vanoxonin with quinquevalent vanadium (NaVO3). Thus, the green and purple complexes were indicated to contain quadriand quinquevalent vanadium, respectively.
BRirroN3> has reported the redox reaction between quadri-and quinquevalent vanadiums in detail.
He showed that in acidic solution quadrivalent vanadium (VO2+ ) is stable but it is easily oxidized by air above pH 3. This air oxidation has also been observed in oxovanadium complexes with uridine4) and catechol5) . Vanoxonin-vanadium complex inhibited thymidylate synthetase under aerobic condition, but under anaerobic condition no inhibition was shown by a complex prepared from vanoxonin and quadrivalent vanadium (Table 1) . These results indicated that vanadium must be quinquevalent for the manifestation of the inhibitory activity.
The structure of vanoxonin is characterized by two types of ligands : catechol and hydroxamic acid.
A number of vanadium complexes with compounds having catechol or hydroxamic acids have been reported4 5 . Therefore, there was a question as to the ligands involved in the complexation of vanoxonin with vanadium. Potentiometric titration of the vanoxonin-vanadium (V5+) complex showed that the pKa' value around 7 attributed to a hydroxyl group on the catechol of vanoxonin could not be observed.
Moreover, L-(N-2,3-dihydroxybenzoyl-O-benzyl)threonine benzyl ester also formed a purple complex with absorption maxima at 534 and 840 nm with vanadium (V5+). These results suggested that vanoxonin-vanadium (V5+) complex was ligated by the hydroxyl groups of the catechols. The molar ratio of vanadium (V5+) to vanoxonin in the complex was found to be 1: 2 by the intensity of absorbance at 845 nm (Fig. 2) .
The solution of the purple vanadium (V5+)-vanoxonin complex was weakly acidic (pH 3) and color Fig. 1 . Absorption spectra of vanoxonin-vanadium complex. Vanadyl sulfate (0.6 pmol in 1 ml of H,O) and vanoxonin (1.2 /Lmol in 2 ml of HO) were mixed under nitrogen. After the visible absorbance spectrum was taken (a), the solution was exposed to air until the absorbance at 845 nm was constant and the spectra was taken (b). Inhibition (%) against the enzyme were shown in the table. The complex, of which the ratio of the ligand to the metal was two, was prepared under air or under the stream of nitrogen by mixing the aq solutions of vanoxonin with the aq solution of vanadyl sulfate or sodium metavanadate. Thymidylate synthetase was assayed as described in experimental section. The concentration of sodium metavanadate was 0.2 mM. The absorbance at 845 nm was measured 2 minutes after mixing vanoxonin and vanadium aq solutions. Vanoxoni n /vanadi um of the complex varied depending on the pH; a brown complex with an absorption maximum at 435 nm formed at neutral pH. The color change was not completely reversible, probably due to partial irreversible oxidation of the ligands. The mid-point of the absorbance change was pH 3.9, which well agreed with the pKa value of hydroxo ligand on dioxovanadium (HOVO2+.=VO2+ +H)°. Therefore, the color change of vanoxonin-vanadium (V5+) complex depending on pH appears to be deprotonation of the hydroxo ligand. Based on these results, the dioxovanadium complex with two mol of vanoxonin was assumed to be the active species for the thymidylate synthetase inhibitor and a possible reaction scheme for the complexation of vanadium with vanoxonin can be proposed as shown in Fig. 3 . When a mixture of one mol of vanadyl sulfate and two mol of vanoxonin was adjusted to pH 7.0 under air, five equivalents of hydroxide were consumed in addition to two mol of hydroxide necessary for neutralizing the carboxylic acid of vanoxonin. This agreed with the amount expected from the reaction scheme. The vanadium (V5+)-vanoxonin complex was unstable in aqueous solution and lost the inhibitory activity against the enzyme in a few hours at room temperature. Vanoxonin-related compounds were prepared and tested for the inhibitory activity against thymidylate synthetase in order to know the structure-activity relationships. The synthesis of L-N-(2,3-dihydroxybenzoyl)threonyl-L-N°-acetylornithine is illustrated in Fig. 4 . The IC50 values are shown in Tables   2, 3 and 4. (The IC50 was defined as the inhibitor concentration necessary to reduce the reaction rate by 50 %). From Table 2 , it is apparent that hydroxyl groups on threonine and Nw-hydroxyornithine, and free carboxylic acid of vanoxonin have relatively little effect on the activity, but the catechol is essential for the inhibitory activity.
Then, the effects of hydroxyl groups on the benzoyl moiety were investigated (Table 3) . Compound with 3,4-dihydroxybenzoyl group showed almost the same activity as compound with 2,3-dihydroxybenzoyl group, but compounds with 2,4-dihydroxy-and 2-hydroxy-3-methoxybenzoyl group exhibited 
The 2-Benzyloxy-3-methoxybenzoic Acid O-Vanillin (3.04 g, 20 mmol), anhydrous K,C03 (11.04 g, 20 mmol) and benzylbromide (3.42 g, 20 mmol) were added in dry Me,,CO (40 ml), refluxed for 8 hours and evaporated. The residue was dissolved in benzene (50 ml), applied to silica gel column (4 x 10 cm), eluted with benzene -EtOAc (4: 1) and evaporated to give 2-benzyloxy-3-methoxybenzaldehyde (3.29 g, 13.6 mmol, 68%), an oil. Rf 0.75 (toluene -EtOAc, 1: 1). 1H NMR (90 MHz, CDC13) 6 3.93 (3H, s, OCH3), 5.2 (2H, s, ArCH2), 7.1 N7.5 (8H, m, ArH), 10.3 (1H, s, CHO). The aldehyde was oxidized to the acid by the method of RASTETTER et a1.14) as follows. The aldehyde (0.97 g, 4 mmol) was dissolved in Me2CO (5 ml) and the solution was diluted with H2O (3 ml). To the cloudy mixture were added sulfamic acid (0.46 g, 4.7 mmol) and sodium chlorite (0.4 g, 4.4 mmol) in portions over 30 minutes. After stirring for 1 hour, the solution was evaporated, the residue was extracted with CHC13 (200 ml), dried (Na2SO4) and re-evaporated. The residue was dissolved in toluene (50 ml), applied to silica gel column (4 x 15 cm), eluted with toluene -EtOAc (1: 1) and evaporated. Crystallization from EtOH gave white crystals in the form of needles (0.49 g, 1.9 mmol, 47%). Rf 0.2 (toluene -EtOAc, l : 1), mp 81°C. 1H NMR (90 MHz, CDC13) 6 3.92 (3H, s, OCH3), 5.2 (2H, s, ArCH2), 7.1 7.6 (8H, m, ArH). Anal Calcd for C15H,404 : C 69.76, H 5.46. Found: C 69.71, H 5.56.
L-(N-2,4-Dibenzyloxybenzoyl-D-benzyl)threonyl-L-N~-acetylornithine
Benzyl Ester L-(N-Boc-O-Benzyl)threonyl-L-N'°-acetylornithine (0.56 g, 1 mmol) was dissolved in dry dichloromethane (10 ml), cooled in an ice-bath and added trifluoroacetic acid (2.0 ml). The solution was stirred for 2 hours at room temp and evaporated.
The residue was extracted with EtOAc (200 ml), washed with saturated NaHC03 and NaCI, dried (Na2SO4) and evaporated to give a ninhydrin positive compound. L-(N-2,3-Dibenzyloxybenzoyl-O-benzyl)threonyl-L-N_-acetylornithine Methyl Ester L-N'-Acetylornithine (0.35 g, 2 mmol) was dissolved in 10% HCl -MeOH (20 ml), stirred for 10 hours at room temp and evaporated. The residue was dissolved in H.,O and applied to Diaion HP-20 column (2 x 10 cm), eluted with 50% aq Me-CO, and evaporated to give the methyl ester of L-N~'-acetylornithine (0.24 g, 1.3 mmol, 65 %). Rf 0.29 (BuOH -AcOH -H2O, 4: 1: 1). 1H NMR (90 MHz, D20) b 1.5 '' 2.3 (4H, m, 3-CH,, 4-CH,), 2.15 (3H, s, CH3CO) , 3.47 (2H, t, J=7 Hz, 5-CH.,), 4.02 (3H, s, OCH3), 4.4 (1H, t, J=6 Hz, 2-CH). The methyl ester and L-(N-2,3-dibenzyloxybenzoyl-O-benzyl)-threonine2) (0.68 g, 1.3 mmol) were dissolved in 5 ml dry DMF. To the solution were added DCC (0.3 g, 1.6 mmol) and HOBt (0.19 g, 1.6 mmol) and stirred for 12 hours at room temp. The resulting precipitate was removed by filtration, EtOAc (100 ml) was added to the filtrate, washed with saturated NaHCO3 and NaCl, dried (Na,SO4) and evaporated. The residue was dissolved in CHC13 (50 ml) and applied to silica gel column (4 x 10 cm), eluted with CHC13 -MeOH (50: 1) and evaporated to give an oily compound (0.44 g, 0.6 mmol, 49 %). L-Na-2,3-Dibenzyloxybenzoyl-L-N,'-acetylornithine Benzyl Ester 2,3-Dibenzyloxybenzoic acid (0.33 g, 1 mmol) and L-Nw-acetylornithine benzyl ester (0.26 g, 1 mmol) were dissolved in distilled THE (10 ml). To the solution were added DCC (0.25 g, 1.2 mmol) and HOBt (0.16 g, 1.2 mmol), and the mixture was stirred for 7 hours at room temp. The resulting precipitate was removed by filtration, EtOAc (100 ml) was added to the filtrate, washed with saturated NaHCO3 and NaCl, dried (Na,S04) and evaporated. The residue was extracted with EtOAc (100 ml), applied to silica gel column (4 x 10 cm), eluted with EtOAc and evaporated to give white powder (0. 
0 mmol) and L-(Nw-acetyl-N°)-benzyloxy)ornithine benzyl ester'~ (0.37 g, 1.0 mmol) were dissolved in distilled THE (10 ml). To the solution were added DCC (0.25 g, 1.2 mmol) and HOBt (0.16 g, 1.2 mmol), and the mixture was stirred for 7 hours at room temp. The resulting precipitate was removed by filtration, EtOAc (150 ml) was added to the filtrate, washed with saturated NaHCO3, and NaCI, dried (Na2SO4) and evaporated. The residue was extracted with toluene (50 ml), applied to silica gel column (2 x 10 cm), eluted with toluene -EtOAc (5: 1) and evaporated. The residue was dissolved in dichloromethane (10 ml), cooled in an ice-bath and trifluoroacetic acid (0.5 ml) was added. Stirring was continued for 2 hours at room temp and the solvent was removed in vacuo. The residue was dissolved in McOH (5 ml) and 10% palladium carbon (50 mg) was added to the solution. After the atomosphere was replaced with hydrogen at atomospheric pressure, stirring was continued for 12 hours at room temp. The undissolved material was removed by filtration and the filtrate was applied to Sephadex LH-20 column ( 
Methotrexate
Bound AH-Sepharose 4B
Methotrexate bound AH-Sepharose 4B was prepared by the method of KAUFMAN et al.l5~ as follows. AH-Sepharose 4B (25 g) was reacted with methotrexate (0.23 g, 0.5 mmol) with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.46 g, 2 mmol) at room temp for 2 hours while stirring and maintaining the pH at 6.4. Then, AcOH (1 ml) was added and stirred for an additional hour. The bright yelloworange gel was washed with large volumes of H2O on a glass filter until the resulting filtrates were colorless. The final product was stored as an aq suspension in the cold and protected from light.
Purification of Thymidylate Synthetase from Ehrlich Ascites Carcinoma Cells of Mice
The enzyme purification was carried out by the method of SHIMIzu et al.10) modified as follows.
Ehrlich ascites carcinoma cells from 30 mice were harvested 7 days after intraperitoneal transplantation
(1 x 108) and disrupted for two minutes with Ultra-Turrax (Janke & Kunnkel KG, IKA-Werk, TP18/2N) in 20 ml of 0.01 M potassium phosphate -0.005 M dithiothreitol -25 /IM deoxyuridylate (pH 6.5) (Buffer A) and centrifuged at 105,000 x g for 1 hour.
The supernatant was applied to Blue-Sepharose CL-6B column (10 ml) and eluted with a linear gradient from Buffer A to Buffer A containing 1 M NaCI.
Ammonium sulfate (37 g/100 ml) were added to the active fraction, stirred for 30 minutes and centrifuged at 12,000 x g for 20 minutes to precipitate the enzyme. The precipitate was dissolved in 10 ml of 0.3 M Tris/HCI -0.005 M dithiothreitol -0.1 mM deoxyuridylate (pH 7.4) (Buffer B) and applied to methotrexate bound affinity column. After washing with Buffer B, the enzyme was eluted with 0.3 M Tris/ HCl -0.005 M dithiothreitol (pH 7.4) and concentrated by placing the eluate in a dialysis bag covered with solid sucrose and dialyzed against Buffer A. The enzyme at this step was purified 1,680-fold over the initial extract and was used in the kinetic studies of inhibition of the vanoxonin-vanadium complexes.
